Clinical Trials Directory

Trials / Unknown

UnknownNCT02892695

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
Sex
All
Age
3 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.

Detailed description

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant. In addition, some patients who enroll to other CD19-CAR-T cell therapy trials might be eligible for this trial if their CD19-CAR-T cells cannot be produced successfully because they have insufficient T cells to allow the CD19-CAR-T cells to be made; their T cells are inefficiently transduced with CAR viruses; or their CAR-T cell expansion is failed.

Conditions

Interventions

TypeNameDescription
BIOLOGICALanti-CD19 CAR-NK cellsThe allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.

Timeline

Start date
2016-09-01
Primary completion
2018-09-01
Completion
2019-09-01
First posted
2016-09-08
Last updated
2016-12-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02892695. Inclusion in this directory is not an endorsement.